News

Cetuximab Extends Survival In Advanced Non-Small Cell Lung Cancer

Robert Pirker
Robert Pirker

ROBERT PIRKER , Medical University of Vienna
Phase III study results have detected improvements in overall survival among patients with advanced non-small cell lung cancer treated with a monoclonal antibody targeted to the epidermal growth factor receptor: EGFR. Robert Pirker told the Turin congress he thinks is an emerging role for EGRF-targeted antibodies in lung cancer for patients who test positive for the epidermal growth factor receptor. He discussed the data with Peter Goodwin.

Download this interview

Similar Interviews

  • Front Line Therapy in Non-Small Cell Lung Cancer
  • Nick Thatcher NICK THATCHER, Christie Hospital, Manchester There is a proven benefit in survival

  • Audio Journal of Oncology 12.7, September 2004
  • Reporting from: - 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, June 5-8, 2004 - New England Journal

  • Debate: Adjuvant Chemotherapy Should Be Standard in Stage I Non-Small Cell Lung Cancer
  • Giorgio Scagliotti Robert Pirker GIORGIO SCAGLIOTTI, University of Turin

    Post a comment